Renal Biomarkers Market Size

Renal Biomarkers Market Analysis

The Renal Biomarkers Market size is estimated at USD 1.5 billion in 2024, and is expected to reach USD 2.20 billion by 2029, growing at a CAGR of 7.53% during the forecast period (2024-2029).

The key factors propelling the growth of the studied market are the rising prevalence of various kidney-related diseases and diseases such as diabetes and high blood pressure, which are the leading causes of renal diseases, coupled with rapid technological advancements in the field of genetics.

The growing burden of various kidney-related health conditions has been on the rise in recent years. The rising prevalence of kidney diseases such as glomerulonephritis, kidney failure, polycystic kidney disease, lupus nephritis, and analgesic nephropathy, kidney infections, among others, are expected to increase the demand for the diagnostics tests used for the identification of renal biomarkers that are used for the diagnosis of these diseases, which ultimately drive the studied market over the forecasted period. For instance, according to the American Kidney Fund Organization Updated data in 2024, around 37 million Americans have kidney disease. Kidney disease is growing at an alarming rate. Hence, the high prevalence of kidney-related diseases in different countries worldwide is expected to boost the studied market over the forecast period.

The rising prevalence of diabetes cases can lead to an increasing prevalence of kidney-related diseases, which is expected to drive the studied market over the forecasted period. For instance, as per the 2022 update from the International Diabetic Federation (IDF), approximately 537 million adults (20-79 years) will be living with diabetes across the globe in 2021, and the number is projected to rise to 643 million by 2030 and 783 million by 2045. Hence, the significant increase in diabetes that can lead to kidney diseases and the huge role of renal biomarkers testing in diagnosing and managing these diseases are expected to drive the studied market over the forecast period.

Additionally, strategic activities by market players, such as partnerships, mergers and acquisitions, and product launches and approvals, are expected to propel the market's growth. For instance, in June 2023, Renalytix PLC reported that the United States Food and Drug Administration (FDA) had granted De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. This affirms KidneyIntelX as a first-in-class, artificial intelligence-enabled prognostic testing platform to guide care management for adults with type 2 diabetes and early-stage chronic (diabetic) kidney disease. Renalytix believes FDA authorization will increase test adoption, inform clinical guidelines, expand insurance coverage, and pursue additional international regulatory approvals.

Similarly, in August 2023, SphingoTec GmbH and Boditech Med Inc. entered into a development agreement aimed at developing the kidney function biomarker penKid. The MDA solidifies the partnership between SphingoTec GmbH and Boditech Med Inc., aiming to support the successful commercialization of the assay for the biomarker penKid on the AFIAS (Automated Fluorescent Immunoassay System) platforms. Such strategic initiatives are projected to drive the market growth significantly over the forecast period.

Thus, due to the aforementioned factors, such as the growing burden of kidney diseases and strategic activities by market players, the renal biomarkers market is expected to grow at a significant rate during the forecast period. However, regulatory and reimbursement system issues may hamper the market's growth over the forecast period.